Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 10/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 4/20 | 0.33 |
| ▸ | PYGM | P11217 | 4/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.32 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.32 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515960 | 1.00 | OPRM1 (0.35) | OPRM1OPRD1OPRK1OPRL1RIPK1 | |
| SCHEMBL515942 | 0.89 | SMYD3 (0.36) | SMYD3TRPM8 | |
| SCHEMBL515941 | 0.89 | SMYD3 (0.36) | SMYD3TRPM8 | |
| SCHEMBL516721 | 0.89 | HTR1A (0.35) | RIPK1SMYD3 | |
| SCHEMBL516720 | 0.89 | HTR1A (0.35) | RIPK1SMYD3 | |
| SCHEMBL516119 | 0.89 | OPRM1 (0.35) | OPRM1OPRD1OPRK1OPRL1RIPK1 | |
| SCHEMBL516120 | 0.89 | OPRM1 (0.35) | OPRM1OPRD1OPRK1OPRL1RIPK1 | |
| SCHEMBL515725 | 0.86 | RIPK1 (0.35) | RIPK1SMYD3 | |
| SCHEMBL515724 | 0.86 | RIPK1 (0.35) | RIPK1SMYD3 | |
| SCHEMBL516102 | 0.70 | OPRL1 (0.40) | OPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455550-B2 | Derivatives of aminocyclobutane or aminocyclobutene, their method of preparation and their use as medical products | PIERRE FABRE MEDICAMENT (FR) | 2013-06-04 | — | — | US | claimed |
| EP-2414323-B1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PF MEDICAMENT (FR) | 2013-03-13 | — | — | EP | claimed |
| US-20120029013-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PIERRE FABRE MEDICAMENT (FR) | 2012-02-02 | — | — | US | claimed |
| US-8455550-B2 | Derivatives of aminocyclobutane or aminocyclobutene, their method of preparation and their use as medical products | PIERRE FABRE MEDICAMENT (FR) | 2013-06-04 | — | — | US | disclosed |
| EP-2414323-B1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PF MEDICAMENT (FR) | 2013-03-13 | — | — | EP | disclosed |
| US-20120029013-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PIERRE FABRE MEDICAMENT (FR) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029013-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | CYP11B2, BCAT1, CYP11B1 | OPRM1 338/4885OPRD1 186/4885OPRK1 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.